Cisplatin is a major therapeutic drug for solid tumors, but can cause severe nephrotoxicity. However, the role and therapeutic potential of hydrogen sulfide (H2S), an endogenous gasotransmitter, in cisplatin-induced nephrotoxicity remain to be defined.
Results:
Cisplatin led to the impairment of H2S production in vitro and in vivo by downregulating the expression level of cystathionine γ-lyase (CSE), which may contribute to the subsequent renal proximal tubule (RPT) cell death and thereby renal toxicity. H2S donors NaHS and GYY4137, but not AP39, mitigated cisplatin-induced RPT cell death and nephrotoxicity. The mechanisms underlying the protective effect of H2S donors included the suppression of intracellular reactive oxygen species generation and downstream mitogen-activated protein kinases by inhibiting NADPH oxidase activity, which may be possibly through persulfidating the subunit p47phox. Importantly, GYY4137 not only ameliorated cisplatin-caused renal injury but also added on more anticancer effect to cisplatin in cancer cell lines.
Innovation and Conclusion:
Our study provides a comprehensive understanding of the role and therapeutic potential of H2S in cisplatin-induced nephrotoxicity. Our results indicate that H2S may be a novel and promising therapeutic target to prevent cisplatin-induced nephrotoxicity. Antioxid. Redox Signal. 29, 455–470.
AhmadA, OlahG, SzczesnyB, WoodME, WhitemanM, and SzaboC. AP39, A mitochondrially targeted hydrogen sulfide donor, exerts protective effects in renal epithelial cells subjected to oxidative stress in vitro and in acute renal injury in vivo. Shock, 45: 88–97, 2016.
3.
AminzadehMA and VaziriND. Downregulation of the renal and hepatic hydrogen sulfide (H2S)-producing enzymes and capacity in chronic kidney disease. Nephrol Dial Transplant, 27: 498–504, 2012.
4.
BeardenSE, BeardRS, and PfauJC. Extracellular transsulfuration generates hydrogen sulfide from homocysteine and protects endothelium from redox stress. Am J Physiol Heart Circ Physiol, 299: H1568–H1576, 2010.
5.
BosEM, WangR, SnijderPM, BoersemaM, DammanJ, FuM, MoserJ, HillebrandsJL, PloegRJ, and YangG. Cystathionine γ-lyase protects against renal ischemia/reperfusion by modulating oxidative stress. J Am Soc Nephrol, 24: 759–770, 2013.
6.
This reference has been deleted.
7.
BrandesRP, WeissmannN, and SchröderK. NADPH oxidases in cardiovascular disease. Free Radi Biol Med, 49: 687–706, 2010.
8.
CaoX and BianJS. The role of hydrogen sulfide in renal system. Front Pharmacol, 7: 385, 2016.
9.
ChatzianastasiouA, BibliSI, AndreadouI, EfentakisP, KaludercicN, WoodME, WhitemanM, Di LisaF, DaiberA, and ManolopoulosVG. Cardioprotection by H2S donors: nitric oxide-dependent and independent mechanisms. J Pharmacol Exp Ther, 358: 431–440, 2016.
10.
CornelisonTL and ReedE. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol, 50: 147–158, 1993.
11.
DasariS and TchounwouPB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 740: 364–378, 2014.
12.
DeLeonER, StoyGF, and OlsonKR. Passive loss of hydrogen sulfide in biological experiments. Anal Biochem, 421: 203–207, 2012.
13.
DugbarteyGJ, BoumaHR, LobbI, and SenerA. Hydrogen sulfide: a novel nephroprotectant against cisplatin-induced renal toxicity. Nitric Oxide, 57: 15–20, 2016.
14.
FloreaAM and BüsselbergD. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers, 3: 1351–1371, 2011.
15.
FrancescatoHD, CostaRS, da SilvaCG, and CoimbraTM. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci, 84: 590–597, 2009.
16.
GersztenkornD, ColettaC, ZhuS, HaY, LiuH, TieH, ZhouJ, SzaboC, ZhangW, and MotamediM. Hydrogen sulfide contributes to retinal neovascularization in ischemia-induced retinopathy. Invest Ophthalmol Vis Sci, 57: 3002–3009, 2016.
17.
GriendlingKK, SorescuD, and Ushio-FukaiM. Nad (p) h Oxidase. Circ Res, 86: 494–501, 2000.
18.
HanSJ, KimJI, ParkJW, and ParkKM. Hydrogen sulfide accelerates the recovery of kidney tubules after renal ischemia/reperfusion injury. Nephrol Dial Transplant, 30: 1497–1506, 2015.
19.
HosgoodS and NicholsonM. Hydrogen sulphide ameliorates ischaemia–reperfusion injury in an experimental model of non-heart-beating donor kidney transplantation. Br J Surg, 97: 202–209, 2010.
20.
IkedaK, MarutaniE, HiraiS, WoodME, WhitemanM, and IchinoseF. Mitochondria-targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in mice. Nitric Oxide, 49: 90–96, 2015.
21.
JhaS, CalvertJW, DuranskiMR, RamachandranA, and LeferDJ. Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling. Am J Physiol Heart Circ Physiol, 295: H801–H806, 2008.
22.
KarwiQG, BornbaumJ, BoenglerK, TorregrossaR, WhitemanM, WoodME, SchulzR, and BaxterGF. AP39, a mitochondria-targeting hydrogen sulfide (H2S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling. Br J Pharmacol, 174: 287–301, 2017.
23.
KimuraY and KimuraH. Hydrogen sulfide protects neurons from oxidative stress. FASEB J, 18: 1165–1167, 2004.
24.
Le TrionnaireS, PerryA, SzczesnyB, SzaboC, WinyardPG, WhatmoreJL, WoodME, and WhitemanM. The synthesis and functional evaluation of a mitochondria-targeted hydrogen sulfide donor, (10-oxo-10-(4-(3-thioxo-3 H-1, 2-dithiol-5-yl) phenoxy) decyl) triphenylphosphonium bromide (AP39). Med Chem Comm, 5: 728–736, 2014.
25.
LeeZW, ZhouJ, ChenCS, ZhaoY, TanCH, LiL, MoorePK, and DengLW. The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One, 6: e21077, 2011.
26.
This reference has been deleted.
27.
LiL, WhitemanM, GuanYY, NeoKL, ChengY, LeeSW, ZhaoY, BaskarR, TanCH, and MoorePK. Characterization of a novel, water-soluble hydrogen sulfide–releasing molecule (GYY4137) new insights into the biology of hydrogen sulfide. Circulation, 117: 2351–2360, 2008.
28.
LinS, VisramF, LiuW, HaigA, JiangJ, MokA, LianD, WoodME, TorregrossaR, and WhitemanM. GYY4137, a slow-releasing hydrogen sulfide donor, ameliorates renal damage associated with chronic obstructive uropathy. J Urol, 196: 1778–1787, 2016.
29.
This reference has been deleted.
30.
LiuM, JiaZ, SunY, ZhangA, YangT. A H 2 S donor GYY4137 exacerbates cisplatin-induced nephrotoxicity in mice. Mediators Inflamm, 2016: 8145785, 2016.
31.
LobbI, JiangJ, LianD, LiuW, HaigA, SahaM, TorregrossaR, WoodM, WhitemanM, and SenerA. Hydrogen sulfide protects renal grafts against prolonged cold ischemia–reperfusion injury via specific mitochondrial actions. Am J Transplant, 17: 341–352, 2017.
32.
LobbI, SonkeE, AboalsamhG, and SenerA. Hydrogen sulphide and the kidney: important roles in renal physiology and pathogenesis and treatment of kidney injury and disease. Nitric Oxide, 46: 55–65, 2015.
MaX, DangC, KangH, DaiZ, LinS, GuanH, LiuX, WangX, and HuiW. Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF-kappaB signalling pathways. Int Immunopharmacol, 28: 399–408, 2015.
35.
MengG, WangJ, XiaoY, BaiW, XieL, ShanL, MoorePK, and JiY. GYY4137 protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats. J Biomed Res, 29: 203–213, 2015.
36.
MengG, ZhuJ, XiaoY, HuangZ, ZhangY, TangX, XieL, ChenY, ShaoY, FerroA, WangR, MoorePK, and JiY. Hydrogen sulfide donor GYY4137 protects against myocardial fibrosis. Oxid Med Cell Longev, 2015: 691070, 2015.
37.
MillerAA, MaxwellKF, ChrissobolisS, BullenML, KuJM, Michael De SilvaT, SelemidisS, HookerEU, DrummondGR, SobeyCG, and Kemp-HarperBK. Nitroxyl (HNO) suppresses vascular Nox2 oxidase activity. Free Radic Biol Med, 60: 264–271, 2013.
38.
MomeniA, HajigholamiA, GeshnizjaniS, and KheiriS. Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study. J Clin Diagn Res, 9: OC11-3, 2015.
39.
NagpureBV and BianJS. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. Oxid Med Cell Longev, 2016: 6904327, 2016.
40.
PablaN, DongG, JiangM, HuangS, KumarMV, MessingRO, and DongZ. Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest, 121: 2709–2722, 2011.
41.
PablaN and DongZ. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int, 73: 994–1007, 2008.
42.
PablaN, MurphyRF, LiuK, and DongZ. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol, 296: F505–F511, 2009.
43.
PanLL, LiuXH, ShenYQ, WangNZ, XuJ, WuD, XiongQH, DengHY, HuangGY, and ZhuYZ. Inhibition of NADPH oxidase 4-related signaling by sodium hydrosulfide attenuates myocardial fibrotic response. Int J Cardiol, 168: 3770–3778, 2013.
44.
PanWJ, FanWJ, ZhangC, HanD, QuSL, and JiangZS. H2S, a novel therapeutic target in renal-associated diseases?. Clin Chim Acta, 438: 112–118, 2015.
45.
PapapetropoulosA, PyriochouA, AltaanyZ, YangG, MaraziotiA, ZhouZ, JeschkeMG, BranskiLK, HerndonDN, WangR, and SzaboC. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A, 106: 21972–21977, 2009.
46.
PegramMD, LiptonA, HayesDF, WeberBL, BaselgaJM, TripathyD, BalyD, BaughmanSA, TwaddellT, and GlaspyJA. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 16: 2659–2671, 1998.
47.
RameshG and ReevesWB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest, 110: 835–842, 2002.
48.
RameshG and ReevesWB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol, 289: F166–F174, 2005.
49.
RiesF and KlasterskyJ. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis, 8: 368–379, 1986.
50.
SchievenGL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem, 5: 921–928, 2005.
51.
SelemidisS, DustingGJ, PeshavariyaH, Kemp-HarperBK, and DrummondGR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res, 75: 349–358, 2007.
52.
SenU, GivvimaniS, AbeOA, LedererED, and TyagiSC. Cystathionine β-synthase and cystathionine γ-lyase double gene transfer ameliorate homocysteine-mediated mesangial inflammation through hydrogen sulfide generation. Am J Physiol Cell Physiol, 300: C155–C163, 2011.
53.
SiowYL, Au-YeungKK, WooCW, and KarminO. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cβ activation. Biochem J, 398: 73–82, 2006.
54.
SongK, WangF, LiQ, ShiYB, ZhengHF, PengH, ShenHY, LiuCF, and HuLF. Hydrogen sulfide inhibits the renal fibrosis of obstructive nephropathy. Kidney Int, 85: 1318–1329, 2014.
55.
SzczesnyB, ModisK, YanagiK, ColettaC, Le TrionnaireS, PerryA, WoodME, WhitemanM, and SzaboC. AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Nitric Oxide, 41: 120–130, 2014.
56.
TakahashiA, KimuraT, TakabatakeY, NambaT, KaimoriJ, KitamuraH, MatsuiI, NiimuraF, MatsusakaT, and FujitaN. Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol, 180: 517–525, 2012.
57.
WangY, LuoX, PanH, HuangW, WangX, WenH, ShenK, and JinB. Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism. Food Chem Toxicol, 83: 251–260, 2015.
58.
WhitemanM, PerryA, ZhouZ, BucciM, PapapetropoulosA, CirinoG, and WoodME. Phosphinodithioate and phosphoramidodithioate hydrogen sulfide donors. In: Chemistry, Biochemistry and Pharmacology of Hydrogen Sulfide, edited by Moore PK and Whiteman M. Switzerland: Springer, 2015, pp. 337–363.
59.
WuYM, ZhangKJ, YueXT, WangYQ, YangY, LiGC, LiN, and WangYG. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin, 30: 467–477, 2009.
60.
XiaM, ChenL, MuhRW, LiPL, and LiN. Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J Pharmacol Exp Ther, 329: 1056–1062, 2009.
61.
YamamotoJ, SatoW, KosugiT, YamamotoT, KimuraT, TaniguchiS, KojimaH, MaruyamaS, ImaiE, MatsuoS, YuzawaY, and NikiI. Distribution of hydrogen sulfide (H(2)S)-producing enzymes and the roles of the H(2)S donor sodium hydrosulfide in diabetic nephropathy. Clin Exp Nephrol, 17: 32–40, 2013.
62.
YangG, CaoK, WuL, and WangR. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1. J Biol Chem, 279: 49199–49205, 2004.
63.
YongQC, LeeSW, FooCS, NeoKL, ChenX, and BianJS. Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning. Am J Physiol Heart Circ Physiol, 295: H1330–H1340, 2008.
64.
YuF, ZhaoJ, TangCS, and GengB. Effect of synthesized GYY4137, a slowly releasing hydrogen sulfide donor, on cell viability and distribution of hydrogen sulfide in mice. Beijing Da Xue Xue Bao, 42: 493–497, 2010.
65.
ZhangX and BianJS. Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system. ACS Chem Neurosci, 5: 876–883, 2014.
66.
ZhouH, DingL, WuZ, CaoX, ZhangQ, LinL, and BianJS. Hydrogen sulfide reduces RAGE toxicity through inhibition of its dimer formation. Free Radic Biol Med, 104: 262–271, 2017.
67.
ZimmermannT, ChvalZ, and BurdaJV. Cisplatin interaction with cysteine and methionine in aqueous solution: computational DFT/PCM study. J Phys Chem B, 113: 3139–3150, 2009.
